REMARKS:

In regard the claim objections, as the examiner can see, the numbering of the claims has been corrected. I apologize for any inconvenience caused by this error.

Claims 1, 5, 6, 13, 14, 16 and 22-24 were rejected under 35 USC 112. The office action states that 'the specification, while being enabling for a method involving administering N-acetylglucosamine-containing carbohydrates or an anti-sense oligonucleotide or antibody to lysozyme, does not reasonably provide enablement for a method involving administering any inhibitor of lysozyme whatsoever.

As the examiner can see, claims 1, 13 and 14 have been amended to state that the agent that can inhibit lysozyme is selected from the group consisting of: N-acetylglucosamine-containing carbohydrates, an anti-sense oligonucleotide to lysozyme and an antibody to lysozyme. Claim 16 has been amended to state that the agent that can inhibit lysozyme is selected from the group consisting of: N-acetylglucosamine-containing carbohydrates and an antibody to lysozyme. Support for these amendments may be found in the previous claims and also at least at page 15, line 21 to page 22, line 4.

Claims 1-6 and 13 were rejected under 35 USC 112. The office action states that 'the specification, while being enabling for a method of treating sepsis or SIRS, or of reversing or reducing myocardial depression, does not reasonably provide enablement for a method of preventing myocardial dysfunction.'

As the examiner can see, claims 1 and 13 have been amended to delete reference to 'preventing'.

It is believed that the claims have been amended so that all of the claims are enabled by the specification as filed. Accordingly, it is believed that all of the outstanding matters have been dealt with and the application is in order for allowance.

Respectfully submitted

Steven N. Mink

PER: /////////
Michael R. Williams
Registration # 45333

August 2, 2007

Winnipeg, Manitoba, Canada Telephone (204) 947-1429 - FAX (204) 942-5723